US Drug Recall Register

FDA Drug Recalls

1,709 recalls · Class III, newest first

Class III · Low risk Terminated

Sodium Ferric Gluconate Complex in Sucrose Injection

Reason Subpotent Drug: Product has an an out of specification in iron assay analysis found during 18 month stability testing.

West-Ward Pharmaceuticals Corp. NDC 0143-9570-10 D-0172-2017
Class III · Low risk Terminated

Amoxicillin for Oral suspension

Reason Labeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed.

West-Ward Pharmaceuticals Corp. NDC 0143-9887-01 D-0147-2017
Class III · Low risk Terminated

Diltiazem HCl Extended-release Capsules

Reason Failed Impurities/Degradation Specifications: OOS results for known compound.

Mylan Pharmaceuticals Inc. NDC 0378-5220-01 D-0151-2017
Class III · Low risk Terminated

Qnasl

Reason Failed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.

Teva Pharmaceuticals USA NDC 59310-210-13 D-0171-2017
Class III · Low risk Terminated

Qnasl

Reason Failed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.

Teva Pharmaceuticals USA NDC 59310-206-06 D-0170-2017
Class III · Low risk Terminated

Kenalog

Reason Failed Stability Specifications: Low Out of Specification results for alcohol content.

Sun Pharmaceutical Industries, Inc. D-0148-2017
Class III · Low risk Terminated

Bupropion Hydrochloride Extended-Release Tablets

Reason Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.

Amerisource Health Services NDC 68001-264-05 D-0137-2017
Class III · Low risk Terminated

FIRST Omeprazole 2mg/mL in FIRST PPI Suspension Compounding Kit

Reason Labeling: Label error on declared strength. Package Insert -Error in the Description section of the package insert refers to the strength as 3mg per mL; however it should state 2mg per mL

CutisPharma, Inc. NDC 65628-070-03 D-0139-2017
Class III · Low risk Terminated

FIRST Omeprazole 2mg/mL in FIRST PPI Suspension Compounding Kit

Reason Labeling: Label error on declared strength. Package Insert -Error in the Description section of the package insert refers to the strength as 3mg per mL; however it should state 2mg per mL

CutisPharma, Inc. NDC 65628-070-05 D-0138-2017
Class III · Low risk Terminated

Ceftriaxone for Injection

Reason Labeling: Missing Label

Sandoz Inc NDC 0409-7332-01 D-0145-2017
Class III · Low risk Terminated

Invokamet

Reason Labeling: Incorrect or Missing Package Insert - Xarelto prescribing information outserts may be affixed to the exterior of Invokamet bottles in place of the Invokamet prescribing information outsert.

Janssen Ortho L.L.C. NDC 50458-543-60 D-0115-2017
Class III · Low risk Terminated

Zeasorb AF

Reason Labeling Not Elsewhere Classified: front labels have the incorrect NDC or 0145-1506-01 instead of the correct NDC of 0145-1506-05 and some back labels have the incorrect indication stating "use for the cure of most jock itch" rather than "use for the cure of most athlete's foot".

GSK Consumer Healthcare NDC 0145-1506-01 D-0142-2017
Class III · Low risk Terminated

Olanzapine tablets

Reason Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.

Dr. Reddy's Laboratories, Inc. NDC 55111-163-30 D-0468-2017
Class III · Low risk Terminated

AHP NIFEdipine Capsules

Reason Presence of Foreign Tablets/Capsules

Amerisource Health Services D-0144-2017
Class III · Low risk Terminated

HCG-Vitamin B12 5000 IU-8 mg in 10 mL vial

Reason Labeling; Error on Declared Strength; product description incorrectly states HCG 7500 units instead of 5000 units. The primary panel is correct

Pharm D Solutions, LLC D-0427-2017
Class III · Low risk Terminated

Testosterone Cypionate 200 mg/mL in Sesame Oil

Reason Incorrect/Undeclared Excipient; product description section of testosterone cypionate incorrectly states "in grapeseed oil" instead of "in sesame oil" . The primary panel is correct

Pharm D Solutions, LLC D-0426-2017
Class III · Low risk Terminated

NIFEdipine Capsules USP

Reason Presence of Foreign Tablets/Capsules

Actavis Elizabeth LLC NDC 0228-2407-10 D-0143-2017
Class III · Low risk Terminated

Paricalcitol Capsules

Reason Failed Impurities/Degradation Specifications: This repackaged product was recalled by its manufacturer due to failed results for impurities.

Amerisource Health Services NDC 60687-106-25 D-0009-2017
Class III · Low risk Terminated

Clonazepam Tablets

Reason Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 16 month timepoint.

Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-882-20 D-0136-2017
Class III · Low risk Terminated

Clonazepam Tablets

Reason Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 15 month timepoint.

Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-881-20 D-0135-2017
Class III · Low risk Completed

Gildess 24 FE 1.5/30

Reason Subpotent Drug; Ethinyl Estradiol

Par Pharmaceutical, Inc. NDC 0603-7610-49 D-0123-2017